



ADEPT - International Conference on Accelerating the Development of Enhanced Pain Treatments, March 2011

WORKSHOP: Academic, government and industry collaborative initiatives






**Euro
pain**



Understanding Chronic Pain and Improving Its Treatment


Andrew SC Rice




Innovative Medicines Initiative 



- IMI Joint Undertaking (IMI JU) is a Public-Private Partnership between:
 - Pharmaceutical industry (European Federation of Pharmaceutical Industries and Associations - EFPIA)
 - European Union (European Commission)
- Aims to speed up the development of better and safer medicines
- Supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe
- Overall goal is to make Europe again the world leader in pharmaceutical research for the benefit of the economy and society, by removing research bottlenecks in the current drug development process


www.imi.europa.eu  








Innovative Medicines Initiative 

- IMI's total budget €2 billion
 - European Commission & EFPIA contribute 50% each
- Annual call for proposals in domains:
 - Safety
 - Efficacy
 - Knowledge Management
 - Education and Training
- Currently in 3rd call – 15 projects launched to date
- Pain Research a "Scientific Priority" in the 1st call (2008)
 - EUROPAIN was funded under this call



www.imi.europa.eu  

Selection Process 

Call definition	Research Agenda	
	Annual Implementation Plan	
	Call with Topics	
Evaluation Stage 1	Expressions of Interest	
	1 st Peer Review	
	Invitation to join for Full Project Proposal	
Evaluation Stage 2	Full Project Proposal	
	2 nd Peer Review	
	Grant Agreement & Project Agreement	

Applicant Consortia may consist of:

- Academia
- Hospitals
- Small and medium sized enterprises
- Patient organisations
- Regulatory authorities


www.imi.europa.eu  




**Euro
pain**


Understanding Chronic Pain and Improving Its Treatment

www.imi.europa.eu


Euro pain EUROPAIN – Academic 


- **London Pain Consortium** (www.lpc.ac.uk)
 - King's College London
 - University College London
 - University of Oxford
 - Imperial College London
- **German Neuropathic Pain Network** (www.neuro.med.tu-muenchen.de/dfns)
 - Christian-Albrechts-Universitaet zu Kiel
 - Ruprecht-Karls Universitaet Heidelberg
 - Technische Universitaet Muenchen
 - BG Universitätsklinikum Bergmannsheil GmbH
 - Klinikum der Johann Wolfgang Goethe-Universitaet
- **Danish Pain Research Centre** (www.dprc.dk)
 - Aarhus University Hospital
 - Region Hovedstaden
 - University of Southern Denmark
- **SME: Neurosciences Technologies S.L.** (www.nsc.anacronico.com)



Euro pain EUROPAIN - EFPIA 

- AstraZeneca (*Co-ordinator*)
- Boehringer Ingelheim
- Pfizer (Wyeth)
- Eli Lilly
- Esteve S.A.
- UCB Pharma
- Sanofi-Aventis
- Grunenthal (*from Dec 2010*)



Euro pain 


STARTING DATE: 01.10.2009


DURATION: 60 months

FINANCING:

- EU funding: € 5,999,344
- EFPIA contribution: € 12,233,114


•TOTAL PROJECT COST: € 18,232,458







-
- Scientific Workpackages**
- Wp1.
 - To identify novel pain mediators
 - Understand the mechanisms of excitability changes at both spinal and supraspinal levels in chronic pain states
 - Wp2.
 - Improve and refine animal models of chronic pain
 - Improve and refine the clinical relevance of endpoints used in chronic pain models
 - Develop methodologies to reduce experimental bias
 - Develop protocol library and training visits
 - Wp3. To establish and validate mechanism-based human pain models

-
- Scientific Workpackages**
- Wp4.
 - To find objective measures of spontaneous pain using microneurography and functional brain imaging
 - To collect detailed phenotypic data on chronic pain patients and correlate with sensitivity to pharmacological agents
 - Elucidate the nature of placebo responses in the pain setting
 - Wp5.
 - Determine psychosocial and clinical risk factors for development of persistent postsurgical pain
 - Test the role of genetic variation in candidate genes as a contributor to chronic pain development


Euro pain Scientific Workpackges 

- Wp6.
 - To extend existing databases and integrate data from existing consortium databases resources
 - Establish database and bioinformatics capability for new data being generated by all other workpackages
- Wp7.
 - A Training Center for QST, including investigator validation
 - QST laboratory validation and quality assurance
- Wp8.
 - EUROPAIN management and governance activities



Euro pain Europain integrative benefit 

Animal models	Sensory characterisation	Model development	Pharmacological modulation	Imaging, electrophysiology	Proteomics, genetics, lipidomics	Data mining
Human pain models						
Chronic Pain Patients						
Patient Chronicity Prediction						



Euro pain Europain Contacts 

- Co-ordinator: **Märta Segerdahl**, AstraZeneca
Marta.Segerdahl@astrazeneca.com
- Deputy Coordinator: **Bernd Sommer**, Boehringer-Ingelheim
Bernd.Sommer@bc.boehringer-ingenheim.com
- Managing Entity of the EU Funding: **Stephen McMahon**, King's College London
stephen.mcmahon@kcl.ac.uk
caroline.abel@kcl.ac.uk
- Liaison between EUROPAIN and ACTION: **Andrew Rice**, Imperial College London
a.rice@imperial.ac.uk



European Steering Committee



"kick-off" meeting Barcelona October 2009
